Strengths and prices
| Strength | Price per vial | Availability | Batch | |
|---|---|---|---|---|
| 5 mg | $25.00 | In stock | BB1-2607-0074 | |
| 10 mg | $40.00 | In stock | BB2-2607-0075 |
Every vial carries its batch code and a QR that opens the certificate of analysis for that exact batch. No account is needed to read one.
What it is
A blend of two synthetic peptides in one vial: BPC-157 (15 amino acids) and TB-500, a trade name for a thymosin beta-4 peptide.
Identity
| Type | Blend of two synthetic peptides |
|---|---|
| Components | BPC-157 and TB-500 (thymosin beta-4) |
| Amounts | As stated on the label and the certificate of analysis |
A blend of two synthetic peptides lyophilized together in one vial. BPC-157 is the pentadecapeptide Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, C62H98N16O22, 1419.5 g/mol (PubChem CID 9941957). TB-500 is thymosin beta-4, a 43-amino-acid N-acetylated peptide, C212H350N56O78S, 4963 g/mol (PubChem CID 45382195); the name is also used for a 7-residue fragment, and the mass on the certificate shows which a batch contains. The vial is offered as 5 mg of each or 10 mg of each. Both peptides are water soluble and contain no cysteine. It is supplied as a white lyophilized powder in a sealed vial.
What the published research covers
Most of the published literature covers the two components separately. A 2026 study of tendon repair in rats included a group given both together.
The two peptides in this vial have separate literatures. BPC-157 is a 15-amino-acid fragment of a gastric protein, studied since the early 1990s mainly in rats by one group in Zagreb; a representative study reported faster healing of a transected Achilles tendon (Staresinic, 2003), and cell-culture work from another laboratory reported more outgrowth, migration and survival of tendon fibroblasts (Chang, 2011). TB-500 is a trade name for thymosin beta-4, a 43-amino-acid actin-binding peptide; in rats with skin wounds it increased re-epithelialization (Malinda, 1999), and it has been studied in mouse cardiac models and in small eye-drop trials.
One published study has examined the two together. In 2026, a Turkish group assigned 32 male rats to four groups after Achilles tendon transection and repair: untreated control, BPC-157 alone, TB-500 alone, and both, each given for four weeks (Bicer, 2026). The authors reported that the TB-500 group had a higher maximum load to failure than controls, that its histological scores for tendon structure were significantly better than those of controls, that the BPC-157 group scored better without reaching significance, and that the combination did no better than either peptide alone. A 2026 review of peptides in sports medicine covers the two as separate agents and notes the thin evidence base (Tewari, 2026).
That is the whole published record on the combination: one animal study with eight rats per group and no human data. Nothing has been published on whether the two peptides interact chemically when lyophilized together, so the certificate of analysis, which confirms each component by mass spectrometry, is the only document that speaks to a given batch.
Regulatory status
Not approved by the FDA for any use. Supplied for laboratory research only.
Testing and documentation
A blend is tested for each component: mass spectrometry confirms that every peptide named on the label is present, and HPLC reports the purity. The certificate of analysis for the batch is reachable from the code on the vial.
Questions laboratories ask
- How much of each peptide is in a vial?
- Two versions are offered: 5 mg BPC-157 with 5 mg TB-500, and 10 mg BPC-157 with 10 mg TB-500, as listed on the product page. The label and the certificate of analysis for the batch state the amounts.
- How is a blend tested?
- By an independent laboratory, for each component: mass spectrometry confirms that both peptides named on the label are present, and HPLC reports the purity. The QR code on the vial opens the certificate for that exact batch.
- What form is it supplied in?
- A lyophilized powder, the two peptides together in one sealed vial, for laboratory research use only.
- Who can order, and how does it ship?
- Orders are accepted under the Research Use Agreement, reaffirmed with every order. Orders ship from Montana, the next business day when paid by card, to United States addresses only and not to freight forwarders.
References
- Bicer O et al. (2026). Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Joint Diseases and Related Surgery. PubMed 42542926
- Staresinic M et al. (2003). Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. Journal of Orthopaedic Research. PubMed 14554208
- Chang CH et al. (2011). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology. PubMed 21030672
- Malinda KM et al. (1999). Thymosin beta4 accelerates wound healing. Journal of Investigative Dermatology. PubMed 10469335
- Tewari K et al. (2026). Peptide Supplements and Their Therapeutic Applications in Sports Medicine. American Journal of Sports Medicine. PubMed 42578445
How it ships
Ordering
Ordering needs an account. A retail account opens as soon as you request it and costs nothing. You pay by card at checkout, or by invoice before the order ships. A wholesale account is reviewed before it opens.
Research use only
This product is a research chemical sold solely for in-vitro laboratory research by qualified persons. It is not a drug, food, supplement or cosmetic, has not been evaluated by the FDA, and must not be administered to any person or animal. Read the full agreement